New drug combo hopes to fight tough cancers in kids and young adults
NCT ID NCT06521567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for participants with cancers like melanoma, Hodgkin lymphoma, brain tumors, and sarcomas.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90048, United States
-
GSK Investigational Site
Iowa City, Iowa, 52242, United States
-
GSK Investigational Site
Hackensack, New Jersey, 07601, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Providence, Rhode Island, 02903, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Brno, 61300, Czechia
-
GSK Investigational Site
Phaha 5, 15006, Czechia
-
GSK Investigational Site
Copenhagen, 2100, Denmark
-
GSK Investigational Site
Bordeaux, 33076, France
-
GSK Investigational Site
Lyon, 69373, France
-
GSK Investigational Site
Paris, 75248, France
-
GSK Investigational Site
Strasbourg, 67098, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Naples, 80123, Italy
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28009, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple therapy shrink untreatable liver tumors?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.